The Company enters into collaborative arrangements for the research and development, manufacture and/or commercialization of drug products and drug candidates. To date, these collaborative arrangements have included out-licenses of and options to out-license internally developed products and drug candidates to other parties, in-licenses of products and drug candidates from other parties, and profit- and cost-sharing arrangements. These arrangements may include non-refundable upfront payments, contingent obligations for potential development, regulatory and commercial performance milestone payments, cost-sharing and reimbursement arrangements, royalty payments, and profit sharing. For detailed descriptions of each arrangement, see the Company’s Annual Report.

For the three and nine months ended September 30, 2026 and 2025, the Company’s other revenue consisted primarily of royalty revenue from IMDELLTRA® sales outside of China under the Amgen collaboration agreement and revenue generated under the Novartis broad markets agreement.


	Three Months Ended	Nine Months Ended
	September 30,	September 30,
			2026	2025	2026	2025
Other Revenue			$	$	$	$
Amgen royalty revenue			25,744	12,169	62,864	26,721
Novartis broad markets revenue			6,869	4,115	17,088	10,957
Other			2,145	987	6,192	1,566
Other Revenue			34,758	17,271	86,144	39,244

During the three and nine months ended September 30, 2026 and 2025, the Company recorded the following amounts related to its collaboration arrangement with Amgen. For a detailed description of the arrangement and related rights and obligations, see the Company’s Annual Report. The Company is still in the commercialization period for XGEVA®, KYPROLIS® and BLINCYTO® in China.

Amounts recorded related to the Company’s portion of the co-development funding on the pipeline assets for the three and nine months ended September 30, 2026 and 2025 were as follows:


	Three Months Ended	Nine Months Ended
	September 30,	September 30,
			2026	2025	2026	2025
			$	$	$	$
BeOne’s portion of the development funding			12,204	59,325	130,070	152,040
Less: Amortization of research and development cost share liability			6,182	29,275	64,345	74,844
Research and development expense			6,022	30,050	65,725	77,196

The Company fulfilled its research and development cost share liability during the three months ended September 30, 2026. As of September 30, 2026 and December 31, 2025, the research and development cost share liability recorded in the Company’s balance sheet was as follows:


	As of
	September 30,	December 31,
	2026	2025
	$	$
Research and development cost share liability, current portion	—	64,345

Total research and development cost share liability	—	64,345

The total reimbursement paid under the commercial profit-sharing agreement for product sales is classified in the income statement for the three and nine months ended September 30, 2026 and 2025 as follows:


	Three Months Ended	Nine Months Ended
	September 30,	September 30,
			2026	2025	2026	2025
			$	$	$	$
Cost of sales - product			5,859	9,962	29,772	26,989
Research and development			(1,332)	(371)	(2,657)	(2,480)
Selling, general and administrative			(32,870)	(24,546)	(86,395)	(73,531)
Total			(28,343)	(14,955)	(59,280)	(49,022)

The Company purchases commercial inventory from Amgen to distribute in China. Inventory purchases amounted to $177,997 and $433,707 for the three and nine months ended September 30, 2026, respectively, and $84,243 and $220,275 for the three and nine months ended September 30, 2025, respectively. Net amounts payable to Amgen was $146,707 and $79,097 as of September 30, 2026 and December 31, 2025, respectively.

The Company has in-licensed the rights to develop, manufacture and, if approved, commercialize multiple development stage drug candidates globally or in specific territories. These arrangements typically include non-refundable upfront payments, contingent obligations for potential development, regulatory and commercial performance milestone payments, cost-sharing arrangements, royalty payments, and profit sharing.

Upfront and milestone payments incurred under these arrangements for the three and nine months ended September 30, 2026 and 2025 are set forth below. All upfront and development milestones were expensed to research and development expense. All regulatory and commercial milestones were capitalized as intangible assets and are being amortized over the remainder of the respective product patent or term of the commercialization agreements.


		Three Months Ended	Nine Months Ended
		September 30,	September 30,
				2026	2025	2026	2025
Payments due to collaboration partners	Classification			$	$	$	$
Upfront payments	Research and development expense			—	191	20,518	691
Development milestones incurred	Research and development expense			757	—	4,070	—
Regulatory and commercial milestone payments	Intangible asset			—	—	—	20,000
Total				757	191	24,588	20,691